The target for acquisition is our common stock, with cumulative results of 0 shares and 0 yen. The upper limit is 1,300,000 shares (3.14% of issued shares) and upper limit of 6,000,000,000 yen, with periods from 2026\/5\/12 to 2026\/12\/31. As of July 31, 2026, the cumulative total is 0 shares and 0 yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"\u30ad\u30fc\u30bb\u30a4\u85ac\u54c1\u5de5\u696d\u682a\u5f0f\u4f1a\u793e","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4547-20260806-01.pdf","jir_short_summary":"The target for acquisition is our common stock, with cumulative results of 0 shares and 0 yen. The upper limit is 1,300,000 shares (3.14% of issued shares) and upper limit of 6,000,000,000 yen, with periods from 2026\/5\/12 to 2026\/12\/31. As of July 31, 2026, the cumulative total is 0 shares and 0 yen.","jir_summary":"### Overview\nThis notice provides the progress of the treasury stock acquisition project based on the board of directors meeting resolution held on May 11, 2026. The target shares are common stock, with an upper limit of 1,300,000 shares (3.14% of issued shares) and the upper total amount of 6,000,000,000 yen. The acquisition periods are from July 1, 2026 to July 31, 2026 (execution-based) and from May 12, 2026 to December 31, 2026, planned as market purchases across multiple periods; as of July 31, 2026, the cumulative total is 0 shares and 0 yen.\n\n### Outlook and Impact on Shareholders\nThis demonstrates the policy of treasury stock acquisition through market purchases. The current cumulative total of 0 shares provides information on the practical avoidance of dilution. Acquisition methods include market purchases via ToSTNeT-3 and entrusted trading agreements, and progress during the period may aim to stabilize shareholder value.","jir_financial_highlights":"Total number of treasury stock acquired: 0 shares (Unclear)\nTotal acquisition value: 0 yen (Unclear)","jir_category":"","jir_hashtags":"#\u30ad\u30fc\u30bb\u30a4\u85ac\u54c1\u5de5\u696d, #\u81ea\u793e\u682a\u8cb7\u3044","jir_key_figures":"Total number of treasury stock acquired: 0 shares (cumulative)\nTotal acquisition value: 0 yen (cumulative)\nUpper limit number of shares: 1,300,000 shares (3.14% of issued shares)","jir_meta_title":"\u3010\u30ad\u30fc\u30bb\u30a4\u85ac\u54c1\u5de5\u696d\u3011Treasury Stock Acquisition Status\uff5cAugust 2026","jir_meta_description":"Details of Keysei Pharmaceutical's treasury stock acquisition, including planned period, upper stock limit and total amount, and current cumulative totals. Planned to be conducted via market purchases.","jir_og_title":"\u3010\u30ad\u30fc\u30bb\u30a4\u85ac\u54c1\u5de5\u696d\u3011Treasury Stock Acquisition Status\uff5cAugust 2026","jir_og_description":"Publicizing the progress of treasury stock acquisition. Explains the upper limit of 1,300,000 shares and 6,000,000,000 yen, with current cumulative totals of 0 shares and 0 yen, and the planned period going forward.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-97479","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n